Apoptotic bodies inhibit inflammation by PDL1–PD1 ‐mediated macrophage metabolic reprogramming
Cell Proliferation · 2024
DOI: 10.1111/cpr.13531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2024. Verfasst von Tao Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Acute Lung Injury, Extracellular Vesicles, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shaanxi Province Key Research and Development Program, the National Key Research and Development Program of China.
Abstract (Originalsprache)
Apoptosis triggers immunoregulation to prevent and suppress inflammation and autoimmunity. However, the mechanism by which apoptotic cells modulate immune responses remains largely elusive. In the context of allogeneic mesenchymal stem cells (MSCs) transplantation, long‐term immunoregulation is observed in the host despite the short survive of the injected MSCs. In this study, utilizing a mouse model of acute lung injury (ALI), we demonstrate that apoptotic bodies (ABs) released by transplanted human umbilical cord MSCs (UC‐MSCs) convert the macrophages from a pro‐inflammatory to an anti‐inflammatory state, thereby ameliorating the disease. Mechanistically, we identify the expression of programmed cell death 1 ligand 1 (PDL1) on the membrane of UC‐MSCs‐derived ABs, which interacts with programmed cell death protein 1 (PD1) on host macrophages. This interaction leads to the reprogramming of macrophage metabolism, shifting from glycolysis to mitochondrial oxidative phosphorylation via the Erk‐dependent pathway in ALI. Importantly, we have reproduced the PDL1–PD1 effects of ABs on metabolic switch using alveolar macrophages from patients with ALI, suggesting the potential clinical implications of developing therapeutic strategies for the patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi International Joint Research Center for Oral Diseases, Center for Tissue Enginee…
- South China Center of Craniofacial Stem Cell Research, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Yan Jin
Förderung
- National Natural Science Foundation of China
- Shaanxi Province Key Research and Development Program
- the National Key Research and Development Program of China
Zitieren
APA
Jiang, T., Xia, Y., Wang, W., Zhao, J., Liu, W., Liu, S., Shi, S., Li, B., He, X., & Jin, Y. (2024). Apoptotic bodies inhibit inflammation by PDL1–PD1 ‐mediated macrophage metabolic reprogramming. Cell Proliferation. https://doi.org/10.1111/cpr.13531
Vancouver
Jiang T, Xia Y, Wang W, Zhao J, Liu W, Liu S, et al. Apoptotic bodies inhibit inflammation by PDL1–PD1 ‐mediated macrophage metabolic reprogramming. Cell Proliferation. 2024. doi:10.1111/cpr.13531
BibTeX
@article{Jiang2024,
author = {Jiang, Tao and Xia, Yanmin and Wang, Wenzhe and Zhao, Jinbo and Liu, Wenhao and Liu, Shiyu and Shi, Songtao and Li, Bei and He, Xiaoning and Jin, Yan},
title = {Apoptotic bodies inhibit inflammation by PDL1–PD1 ‐mediated macrophage metabolic reprogramming},
journal = {Cell Proliferation},
year = {2024},
doi = {10.1111/cpr.13531}
}
EUVIMED